Table 1.
Key characteristics of included studies.
| Study no. | Author, year and country | Study period | Sample characteristics |
Quality appraisal | |||
|---|---|---|---|---|---|---|---|
| Sample size | Median/mean age in years | Gender |
|||||
| Male | Female | ||||||
| 1. | Di Noia et al., 2021,37 Italy | 1/03/2021 to 20/03/2021 | 914 | 62 (21–97) | 39% | 61% | Fair |
| 2. | Barrière et al., 2021,35 France | 1/11/2020 to 12/12/2020 | 999 | 67 (18–97) | 43.9% | 56.1% | Fair |
| 3. | Brodziak A et al., 2021,31 Poland | 26/01/2021 to 18/02/2021 | 635 | 53 (18–89) | 19.8% | 80.2% | Good |
| 4. | Conti et al., 202141 | 1/12/2020 to 21/12/2020 | 6516 | 63.93 ± 12.28 | 40.2% | 59.8% | Fair |
| 5. | Villarreal-Garza et al., 2021,36 Mexico | 12/03/2021 to 26/03/2021 | 540 | 49 (23–85) | – | 100% | Fair |
| 6. | Waters et al., 2021,38 USA | 10/2020– to 01/2021 | 342 | 29.5 ± 6.5 | 38.9% | 61.1% | Fair |
| 7. | Mejri et al., 2021,33 Tunisia | 02/2021 to 05/2021 | 329 | 54 ± 13.4 | 21.3% | 78.7% | Good |
| 8. | Yang He et al., 2021,20 China - Hubei | Not indicated | 115 | – | – | – | Fair |
| 9. | Moujaess et al., 2021,21 Lebanon | 25/01/2021– to 12/02/2021 | 111 | 61 (23–85) | 33.3% | 66.7% | Fair |
| 10. | Brzuszek et al., 2021,40 Poland | Not indicated | 280 | – | 73% | 27% | Fair |
| 11. | Chun et al., 2021,31 Korea | 02/2021– to 04/2021 | 993 | 57.4 ± 12.0 | 28.3% | 71.7% | Fair |
| 12. | Chan et al., 2021,34 China–Hong Kong | 31/01/2021– to 15/02/2021 | 660 | – | 34.5% | 65.5% | Good |
| 13. | Brko et al., 2021,47 Serbia | 1/07/2021– to 15/08/2021 | 767 | – | – | – | Fair |
| 14. | Heyne et al., 2022,25 Germany | 09/2021– to 11/2021 | 438 | 61.4 ± 12.3 | 39.5% | 60.5% | Fair |
| 15. | De Sousa et al., 2022,28 Portugal | 08/03/2021– to 02/04/2021 | 169 | 61 (29–82) | 35.5% | 64.5% | Good |
| 16. | Cerić et al., 2022,45 Bosnia and Herzegovina | 22/10/2021– to 30/11/2021 | 1063 | 61.9 ± 11.5 | 34.3% | 65.7% | Fair |
| 17. | Waters et al., 2022,23 USA | 10/2020– to 01/2021 | 341 | – | 39.3% | 60.7% | Fair |
| 18. | Roupa et al., 2021,24 Cyprus | 22/01/2021– to 12/02/2021 | 211 | 52.6 ± 12.4 | 34.6% | 64.9% | Fair |
| 19. | Khiari et al., 2021,43 Tunisia | 02/2021 | 200 | 54.4 ± 12.7 | 34.5% | 65.5% | Good |
| 20. | Nguyen et al., 2021,42 Australia | 30/07/2021– to 07/08/2021 | 1073 | 62 ± 11.97 | 43.2% | 56.2% | Good |
| 21. | Peng et al., 2021,46 China | 05/06/2021– to 12/06/2021 | 744 | 48 (40–54) | 0.4% | 99.6% | Good |
| 22. | Erdem and Karaman, 2021,29 Turkey | 05/2021– to 06/2021 | 300 | 55.16 ± 12.91 | 35% | 65% | Fair |
| 23. | Admasu, 2021,44 Ethiopia | 05/2021– to 08/2021 | 422 | 35.7 ± 6.86 | 42.8% | 57.2% | Good |
| 24. | Zhuang et al., 2021,22 China | 03/2021– to 05/2021 | 324 | – | – | – | Good |
| 25. | Foster et al., 2021, Germany | 15/03/2021– to 28/07/2021 | 120 | Breast cancer: 57 (23–85) Gynaecological cancer: 56 (34–78) |
3.33% | 96.67% | Fair |
| 26. | Hong et al., 2021,30 China | 17/06/2021– to 03/09/2021 | 2158 | – | 48.89% | 51.11% | Good |
| 27. | Marijanović et al., 2021,48 Bosnia and Herzegovina | 02/2021 | 364 | 61.6 ± 11.2 | 38.5% | 61.5% | Good |
| 28. | Couderc et al., 2021,27 France | 18/01/2021– to 07/05/2021 | 150 | 81 ± 0.5 | 61.3% | 38.7% | Fair |
| 29. | Noronha et al., 2021,32 India | 07/05/2021– to 10/06/2021 | 435 | 58 (52–65) | 73.8% | 26.2% | Fair |